GAMMAGARD LIQUID IV
Intravenous (IV) Administration
Sustained Protection Against Infection1
In the IV administration clinical study of 61 patients with PI, GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% Solution was shown to be effective at a dose of 300 to 600 mg/kg every 3 to 4 weeks for 12 months
|There were no cases of validated acute serious bacterial
|No patients were hospitalized due to infection|
|There were 4 occurrences of validated other bacterial infections reported: urinary tract infection (1), gastroenteritis (1), and ear infection (2)|
In a total of 1,812 infusions in the clinical study, the most common side effect for GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% Solution was headache (5.2%).
The most common side effects (seen in ≥5% of patients) were headache, fatigue, fever, nausea, chills/shaking chills, pain in the hands or feet, diarrhea, migraine, dizziness, vomiting, cough, hives, asthma, sore throat, rash, joint pain, muscle pain, swelling in the arms or legs, itching, and heart murmur.
95% of the 400 side effects reported in this study
Please see below for additional Important Safety Information.
GAMMAGARD LIQUID is formulated with1:
- Added Sugars1
- Added Sodium1
- Added Preservatives1
- Stabilized and buffered with glycine1 for those patients in whom additives may be a concern
- The packaging is not made with natural rubber latex1
GAMMAGARD LIQUID Brochure
To learn more about PI and GAMMAGARD LIQUID IV treatment, you can download the brochure from our Resources page.
Reference: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc.